Proposal to list medical devices supplied by Intermed Medical Limited
PHARMAC is seeking feedback on a proposal to list a range of medical devices in Part III of Section H of the Pharmaceutical Schedule from 1 November 2018, through a provisional agreement with Intermed Medical Limited.
Closes: 4pm Wednesday, 26 September 2018.
Proposal to list sapropterin for use in pregnancy by women with phenylketonuria
PHARMAC is seeking feedback on a proposal to fund sapropterin tablets, a treatment for the rare condition phenylketonuria (PKU), for women who are pregnant or actively planning a pregnancy and require pharmacological support to manage PKU in pregnancy.
Consultation closes at 12 noon on Monday, 17 September 2018.
Proposal to list a range of orthopaedic implants and associated products supplied by Mathys Limited
PHARMAC is seeking feedback on a proposal to list a range of orthopaedic implants and associated products supplied by Mathys Limited ("Mathys") in Part III of Section H of the Pharmaceutical Schedule from 1 November 2018.
Consultation closes at 5pm on Thursday, 20 September 2018.
Proposal to move to one funded brand of lamotrigine (Logem)
PHARMAC is seeking feedback on a proposed change to the funding of lamotrigine dispersible tablets used in the treatment of epilepsy and/or bipolar disorder.
Consultation closes at 4 pm on Wednesday, 26 September 2018.
Proposal to list urology, ostomy and continence products supplied by Convatec (New Zealand) Limited
PHARMAC is seeking feedback on a proposal to list a range of urology, ostomy and continence products in Part III of Section H of the Pharmaceutical Schedule from 1 November 2018, through a listing agreement with Convatec (New Zealand) Limited
Closes: 4pm Tuesday, 18 September 2018.
Update on proposal to fund a pangenotypic hepatitis C treatment - glecaprevir and pibrentasvir (Maviret)
PHARMAC have determined that we require additional time to consider the issues raised as a result of our consultation of 20 July 2018 before a decision can be made on the proposal.
Proposal to list medical devices supplied by Jackson Allison Medical & Surgical Limited
PHARMAC is seeking feedback on a proposal to list a range of medical devices in Part III of Section H of the Pharmaceutical Schedule from 1 November 2018, through a provisional agreement with Jackson Allison Medical & Surgical Limited.
Closes: 4pm Friday, 14 September 2018.
Notice of Information - Supply of laboratory equipment and consumables
This Notice of Information is to provide advance notification to the market of PHARMAC's intention to release an RFP (Request for Proposal) for the supply of laboratory equipment and consumables. The RFP is intended to be released via the Government Electronic Tenders Service (GETS) in mid-September 2018.
Proposal to list continence products supplied by Universal Specialities Limited
PHARMAC is seeking feedback on a proposal to list a range of continence products in Part III of Section H of the Pharmaceutical Schedule from 1 November 2018, through a listing agreement with Universal Specialities Limited.
Closes: 4pm Thursday, 13 September 2018.
Proposal to change the funded brand of epoetin alfa
PHARMAC is seeking feedback on a proposed change to the funded brand of epoetin alfa [erythropoietin alfa] injections used in the treatment of chronic renal failure and myelodysplasia.
Consultation closes at 4 pm on Monday, 10 September 2018.
Proposal to list nintedanib (Ofev), and remove restrictions from tiotropium bromide (Spiriva)
PHARMAC is seeking feedback on a proposal to list nintedanib (Ofev) and remove the current funding restrictions from tiotropium (Spiriva and Spiriva Respimat) from 1 October 2018, through a provisional agreement with Boehringer Ingelheim NZ Limited.
Consultation closes at 4 pm on Tuesday, 4 September 2018.
Proposal to list medical devices supplied by Draeger New Zealand Limited
PHARMAC is seeking feedback on a proposal to list a range of anaesthesia and respiratory care products in Part III of Section H of the Pharmaceutical Schedule from 1 October 2018 through a provisional agreement with Draeger New Zealand Limited.
Closes: 4pm Friday, 31 August 2018.
2018/19 invitation to tender (suppliers)
PHARMAC is seeking feedback from pharmaceutical suppliers and interested parties on:
- A proposal to tender certain pharmaceuticals for sole supply;
- The draft process and terms and conditions for the 2018/19 Invitation to Tender (2018/19 Tender); and
- Commercial proposals as an alternative to tendering.
PHARMAC welcomes all feedback on the draft 2017/18 Tender.
Alternative commercial proposal responses due by 5 pm, Monday 27 AUGUST 2018
All other consultation responses due by 5 pm, Thursday 6 SEPTEMBER 2018
2018/19 invitation to tender (medical)
PHARMAC is seeking feedback from medical groups, DHB hospital pharmacies and other interested parties on:
- A proposal to tender certain pharmaceuticals for sole supply; and
- The draft process and terms and conditions for the 2018/19 Invitation to Tender (2018/19 Tender).
PHARMAC welcomes all feedback on the 2018/19 Tender.
All responses are due by 5pm, Thursday 6 September 2018
Proposal to list Interventional Radiology and respiratory products from Getz Healthcare Ltd
PHARMAC is seeking feedback on a proposal to list a range of interventional radiology and respiratory care products in Part III of Section H of the Pharmaceutical Schedule from 1 October 2018 through a provisional agreement with Getz Healthcare Ltd (‘Getz’).
Consultation closes at 5pm on Friday, 17 August 2018.
Proposal to list medical devices supplied by EBOS Group Limited and Talgram Health (NZ) Ltd
PHARMAC is seeking feedback on a proposal to list a range of medical devices in Part III of Section H of the Pharmaceutical Schedule from 1 October 2018 through provisional agreements with EBOS Group Limited and Talgram Health (NZ) Ltd.
Consultation closes at 4pm on Friday, 17 August 2018.
Proposal to list medical devices supplied by Device Technologies New Zealand Limited and Medipak Surgical NZ Limited
PHARMAC is seeking feedback on a proposal to list a range of medical devices in Part III of Section H of the Pharmaceutical Schedule from 1 October 2018, through individual provisional agreements with the following suppliers (Closes 15 August 2018).
Proposal to fund a pangenotypic hepatitis C treatment - glecaprevir and pibrentasvir (Maviret)
PHARMAC is seeking feedback on a proposal to fund a pangenotypic treatment for chronic hepatitis C infection, glecaprevir and pibrentasvir (Maviret), through a provisional agreement with AbbVie Ltd. And we also seek feedback on the proposed distribution arrangements.
Consultation closes at 5 pm on Monday, 13 August 2018.
Proposal to modify the transition between funded brands in the Schedule
PHARMAC is seeking feedback on a proposal to simplify the transition period for changes made to community medicines by removing the referencing pricing period during brand changes.
Consultation closes at 5 pm, Friday 10 August 2018.
Proposal to list Interventional Radiology products supplied by Bio-Excel (New Zealand) Ltd and Biotronik Australia PTY Limited
PHARMAC is seeking feedback on a proposal to list a range of Interventional Radiology Products in Part III of Section H of the Pharmaceutical Schedule from 1 September 2018 through provisional agreements with Bio-Excel (New Zealand) Ltd (‘Bio-Excel’) and Biotronik Australia PTY Limited (“Biotronik”).
Consultation closes at 5pm on Friday, 27 July 2018.